Work

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(21)00639-6

Authors: K. Nakagawa, J.C.-H. Yang, K. Park, Y. Ohe, Y.-L. Wu, J. Gainor, A. Blackwood-Chirchir, R. Yang, I.-F. Chang, T. Mok

Institutions: Kindai University Hospital, National Taiwan University Hospital, Samsung Medical Center, National Cancer Center Hospital, Guangdong General Hospital, Massachusetts General Hospital, Bristol-Myers Squibb (United States), Chinese University of Hong Kong

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2586113026

FWCI: 0.299

Cites:

Cited by: 8

Related to: 10